Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration

 Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration

Shots:

  • The company starts enrolling patients in the P-III MYLIGHT study to evaluate the safety and efficacy of biosimilar aflibercept vs Eylea in patients with nAMD for 48wks. The study is expected to enroll 460 patients across 20 countries
  • The study is a part of a biosimilar development program that includes analytical, pre/ clinical data. The study focuses to confirm the efficacy & safety of biosimilar aflibercept to the Eylea
  • The company has eight marketed biosimilar medicines globally and 15+ molecules in the pipeline and focuses to expand the access to affordable biologics

Click here to­ read full press release/ article | Ref: Sandoz | Image: Sandoz

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post